70748-105 : Dapagliflozin 5 mg Oral Tablet


NDC: 70748-105
Labeler: Lupin Pharmaceuticals, Inc.
Product Type: Human Prescription Drug
Drug Name:  Dapagliflozin
Dosage Form: Oral Tablet
Application #: ANDA211531
Rev. Date: 


NDC Package Codes:

  • 70748-105-01: 100 TABLET IN 1 BOTTLE (70748‑105‑01)
  • 70748-105-02: 500 TABLET IN 1 BOTTLE (70748‑105‑02)
  • 70748-105-06: 30 TABLET IN 1 BOTTLE (70748‑105‑06)
  • 70748-105-09: 90 TABLET IN 1 BOTTLE (70748‑105‑09)

Active Ingredients:

  • Dapagliflozin

Dosage Strength:

  • 5 mg

Pharmaceutical Classes:

  • Sodium-Glucose Cotransporter 2 Inhibitor [EPC]
  • Sodium-Glucose Transporter 2 Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 70748-106 Dapagliflozin 10 mg Oral Tablet by Lupin Pharmaceuticals, Inc.
  • 50090-7056 Dapagliflozin 5 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-7057 Dapagliflozin 10 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 63629-3253 Dapagliflozin 10 mg Oral Tablet, Film Coated by Bryant Ranch Prepack
  • 66993-456 Dapagliflozin 5 mg Oral Tablet, Film Coated by Prasco, LLC
  • 66993-457 Dapagliflozin 10 mg Oral Tablet, Film Coated by Prasco, LLC

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 70748-105 QR Code

< Prev: 70746-001Next: 70748-106 >

Related Discussions:

Dapagliflozin 10 mg Side Effects
I am an 82-year-old man and have had type 2 diabetes since 2012. My diabetes is currently under control. Recently, my ph...
fraxiga (dapagliflozin)
looking for any information on this drug used for type 2 diabetic it's supposed to be a new drug ## Hello, Dennis! H... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.